Innoviva/$INVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innoviva
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Ticker
$INVA
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
127
ISIN
US45781M1018
Website
Innoviva Metrics
BasicAdvanced
$1.2B
-
-$0.95
0.36
-
Price and volume
Market cap
$1.2B
Beta
0.36
52-week high
$22.00
52-week low
$16.67
Average daily volume
1M
Financial strength
Current ratio
2.479
Quick ratio
2.236
Long term debt to equity
49.262
Total debt to equity
80.233
Interest coverage (TTM)
9.00%
Profitability
EBITDA (TTM)
222.651
Gross margin (TTM)
88.80%
Net profit margin (TTM)
-16.15%
Operating margin (TTM)
51.29%
Effective tax rate (TTM)
-28.92%
Revenue per employee (TTM)
$2,910,000
Management effectiveness
Return on assets (TTM)
9.74%
Return on equity (TTM)
-8.84%
Valuation
Price to revenue (TTM)
3.313
Price to book
1.9
Price to tangible book (TTM)
2.88
Price to free cash flow (TTM)
6.251
Free cash flow yield (TTM)
16.00%
Free cash flow per share (TTM)
313.05%
Growth
Revenue change (TTM)
18.70%
Earnings per share change (TTM)
-142.34%
3-year revenue growth (CAGR)
-2.29%
10-year revenue growth (CAGR)
36.80%
3-year earnings per share growth (CAGR)
-23.93%
10-year earnings per share growth (CAGR)
-0.31%
What the Analysts think about Innoviva
Analyst ratings (Buy, Hold, Sell) for Innoviva stock.
Bulls say / Bears say
Innoviva's core royalty platform demonstrated strong performance, receiving GSK royalties of $60.5 million in Q3 2024, marking a 6% year-over-year growth. (businesswire.com)
The company's marketed portfolio achieved U.S. net product sales of $19.7 million in Q3 2024, reflecting a 68% year-over-year growth, indicating robust demand for its products. (businesswire.com)
Innoviva's subsidiary, Innoviva Specialty Therapeutics, is on track to submit a New Drug Application for zoliflodacin, a potential first-in-class, single-dose oral drug for the treatment of uncomplicated gonorrhea, to the U.S. FDA in early 2025. (businesswire.com)
Innoviva reported a net loss of $46.6 million in Q1 2025, a significant decline from a net income of $36.5 million in Q1 2024, indicating financial challenges. (businesswire.com)
The company's total debt stood at $377.8 million as of fiscal year 2024, with a negative debt-to-equity ratio due to negative total equity, raising concerns about its financial leverage. (dcfmodeling.com)
Innoviva's operating income decreased from $474 million in 2022 to $167 million in 2024, reflecting a downward trend in operational profitability. (macrotrends.net)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Innoviva Financial Performance
Revenues and expenses
Innoviva Earnings Performance
Company profitability
Innoviva News
AllArticlesVideos
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
Business Wire·1 month ago
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
Business Wire·2 months ago
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innoviva stock?
Innoviva (INVA) has a market cap of $1.2B as of July 21, 2025.
What is the P/E ratio for Innoviva stock?
The price to earnings (P/E) ratio for Innoviva (INVA) stock is 0 as of July 21, 2025.
Does Innoviva stock pay dividends?
No, Innoviva (INVA) stock does not pay dividends to its shareholders as of July 21, 2025.
When is the next Innoviva dividend payment date?
Innoviva (INVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innoviva?
Innoviva (INVA) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.